Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | PTEN loss |
Therapy | KX2-391 + Oxaliplatin |
Indication/Tumor Type | ovarian mucinous neoplasm |
Response Type | no benefit |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PTEN loss | ovarian mucinous neoplasm | no benefit | KX2-391 + Oxaliplatin | Preclinical | Actionable | In a preclinical study, KX2-391 and Eloxatin (oxaliplatin) combination treatment did not show improved tumor suppression in xenograft models of ovarian mucinous carcinoma harboring PTEN loss when compared to single agent treatment (PMID: 24100628). | 24100628 |
PubMed Id | Reference Title | Details |
---|---|---|
(24100628) | Targeting SRC and tubulin in mucinous ovarian carcinoma. | Full reference... |